AVX Pharma, a CataloniaBio member company, has announced it is beginning phase II clinical trials to assess the safety and efficacy of its ophthalmological solution AVX-012 in patients with mild to moderate cases of dry-eye syndrome.

“AVX-012 was safe and well tolerated at all doses tested in the Phase I trial. Now the initiation of this Phase II trial marks another important milestone for a disease suffered by millions of patients that are still lacking of effective treatment options,” said Patrick Tresserras, President and CEO of AVX Pharma. It is a double-blind placebo-controlled study in patients over 28 days.

The prevalence of dry-eye syndrome in the United States, Australia and Europe is between 5% and 15% and between 30% and 50% in Asia. The therapeutic market for dry eye is expected to hit $4.6 million by 2024.

For more information on this clinical trial, go to Clinicaltrials.gov (ID code NCT03162094) or the AVX Pharma website.

Photo: Patrick Tresserras, CEO of AVX Pharma, at the Barcelona Science Park - © AVX Pharma